2,636 Shares in Amedisys, Inc. (NASDAQ:AMED) Acquired by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP purchased a new stake in Amedisys, Inc. (NASDAQ:AMED) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 2,636 shares of the health services provider’s stock, valued at approximately $239,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its position in shares of Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after acquiring an additional 124 shares during the period. HBW Advisory Services LLC bought a new position in Amedisys during the 4th quarter worth $38,000. Johnson Financial Group Inc. bought a new position in Amedisys during the 4th quarter worth $55,000. Vestcor Inc acquired a new position in Amedisys in the 4th quarter valued at $73,000. Finally, Venturi Wealth Management LLC lifted its position in shares of Amedisys by 397.4% during the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after acquiring an additional 779 shares during the period. 94.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AMED. Stephens restated an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $100.00 target price on shares of Amedisys in a report on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $100.75.

Amedisys Trading Up 0.2%

Shares of AMED opened at $95.36 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of 37.84, a PEG ratio of 1.78 and a beta of 0.96. The business’s fifty day moving average is $92.97 and its 200-day moving average is $91.65.

Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.12. The firm had revenue of $594.78 million for the quarter, compared to analysts’ expectations of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.03 earnings per share. Equities analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.